• Ang Li, Renato D Lopes, and David A Garcia.
• Division of Hematology, Department of Medicine, University of Washington Medical Center, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA. Electronic address: ali2015@uw.edu.
• Hematol. Oncol. Clin. North Am. 2016 Oct 1; 30 (5): 1053-71.

AbstractDirect oral anticoagulants (DOACs) have been approved for the treatment of venous thromboembolism and atrial fibrillation based on randomized controlled trials (RCTs) of direct comparisons with vitamin K antagonists. Despite having more than 100,000 patients enrolled, safety and efficacy are debated in selected populations. Although DOACs are reviewed as a class of anticoagulant, pharmacokinetic differences exist such that different medications may be beneficial in distinct clinical settings. Synthesizing available evidence based on phase III RCTs, post hoc subgroup analyses, and pooled metaanalyses, this review provides an overview of DOACs and scrutinizes individual differences in their applications for the special populations.Copyright © 2016 Elsevier Inc. All rights reserved.

19 keywords...

hide…